Compare · IMAX vs TMO
IMAX vs TMO
Side-by-side comparison of Imax Corporation (IMAX) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- IMAX operates in Consumer Discretionary, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $177.93B, about 85.1x IMAX ($2.09B).
- Over the past year, IMAX is up 49.0% and TMO is up 12.2% - IMAX leads by 36.8 points.
- IMAX has been more active in the news (13 items in the past 4 weeks vs 10 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 10 for IMAX).
- Company
- Imax Corporation
- Thermo Fisher Scientific Inc
- Price
- $35.96-5.44%
- $470.74-1.80%
- Market cap
- $2.09B
- $177.93B
- 1M return
- -6.94%
- -4.81%
- 1Y return
- +48.96%
- +12.18%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 13
- 10
- Recent ratings
- 10
- 25
Imax Corporation
IMAX Corporation, together with its subsidiaries, operates as an entertainment technology company worldwide. It offers cinematic solution comprising proprietary software, theater architecture, intellectual property, and specialized equipment. The company offers IMAX Digital Re-Mastering (DMR), a proprietary technology that digitally enhances the image resolution, visual clarity, and sound quality of motion picture films for projection on IMAX screens; IMAX theater systems to exhibitor customers through sales, leases, and joint revenue sharing arrangements; digital projection systems; a digital theater control systems; and a digital audio systems. It also provides proactive and emergency maintenance services to the IMAX network; licenses film content and distributes large-format documentary films; film post-production and quality control services for large-format films, and digital post-production services; owns and operates IMAX theaters; and rents 2D and 3D large-format film and digital cameras, as well as offers production advice and technical assistance services to documentary and Hollywood filmmakers. The company markets its theater systems through a direct sales force and marketing staff to science and natural history museums, zoos, aquaria, and other educational and cultural centers, as well as theme parks, private home theaters, tourist destination sites, fairs, and expositions. It owns or otherwise has rights to trademarks and trade names, which include IMAX, IMAX Dome, IMAX 3D, IMAX 3D Dome, Experience It in IMAX, The IMAX Experience, An IMAX Experience, An IMAX 3D Experience, IMAX DMR, DMR, IMAX nXos, and Films To The Fullest. As of December 31, 2020, the company had a network of 1,650 IMAX theater systems comprising 1,562 commercial multiplexes, 12 commercial destinations, and 76 institutional facilities operating in 81 countries and territories. IMAX Corporation was founded in 1967 and is headquartered in Mississauga, Canada.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest IMAX
- SEC Form 10-Q filed by Imax Corporation
- Imax Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- IMAX Corporation Reports First Quarter 2026 Results
- HOYTS Cinemas and IMAX Expand Partnership with Ten New IMAX with Laser Locations Across Australia and New Zealand
- Chief Executive Officer Gelfond Richard L sold $333,814 worth of shares (8,943 units at $37.33) as part of a pre-agreed trading plan and converted options into 8,943 shares (SEC Form 4)
- SEC Form DEF 14A filed by Imax Corporation
- SEC Form 4 filed by Gelfond Richard L
- Imax Corporation filed SEC Form 8-K: Leadership Update
- IMAX Corporation to Announce First-Quarter 2026 Financial Results and Host Conference Call
- SEC Form 4 filed by Gelfond Richard L
Latest TMO
- SEC Form 10-Q filed by Thermo Fisher Scientific Inc
- President & COO Pettiti Gianluca sold $185,064 worth of shares (400 units at $462.66) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 25,051 units (SEC Form 4)
- Thermo Fisher Scientific to Host Investor Day
- Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc